Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Company Description (as filed with the SEC)
Biota is a leading anti-infective drug development company, based in Rockville, Maryland, with key expertise in respiratory diseases, particularly influenza. Biota developed its first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza(TM). Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota also has an advanced program for the treatment of human rhinovirus (HRV) infection, with a successfully completed Phase IIb study in asthmatic subjects. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza antivirals, of which the lead product, laninamivir, is approved and marketed as lnavir(R) in Japan. Biota also holds a contract from the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced development of laninamivir in the USA. ... More ...